# EDGAR Filing Document

**Accession Number:** 0001816736
**File Stem:** 0001193125-23-004732
**Filing Date:** 2023-1
**Character Count:** 35532
**Document Hash:** 24604092ee0219d3d30422e345416fcc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-004732.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001193125-23-004732

**CONFORMED SUBMISSION TYPE**: SC 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**GROUP MEMBERS**: ACCESS INDUSTRIES HOLDINGS LLC

**GROUP MEMBERS**: ACCESS INDUSTRIES MANAGEMENT, LLC

**GROUP MEMBERS**: LEN BLAVATNIK

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Disc Medicine, Inc.
- **CENTRAL INDEX KEY:** 0001816736
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 851613057
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91633
- **FILM NUMBER:** 23518086

**BUSINESS ADDRESS:**
- **STREET 1:** 300 ONE KENDALL SQUARE, 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** (617) 401-4400

**MAIL ADDRESS:**
- **STREET 1:** 300 ONE KENDALL SQUARE, 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Gemini Therapeutics, Inc. /DE
- **DATE OF NAME CHANGE:** 20210209

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FS Development Corp.
- **DATE OF NAME CHANGE:** 20200702
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AI DMI LLC
- **CENTRAL INDEX KEY:** 0001890993
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D

**BUSINESS ADDRESS:**
- **STREET 1:** C/O ACCESS INDUSTRIES, INC.
- **STREET 2:** 40 WEST 57TH STREET, 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 212-247-6400

**MAIL ADDRESS:**
- **STREET 1:** C/O ACCESS INDUSTRIES, INC.
- **STREET 2:** 40 WEST 57TH STREET, 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**SCHEDULE 13D** 

**Under the Securities Exchange Act of 1934** 

**(Amendment No.)\*** 

------

## Disc Medicine, Inc.
**(Name of Issuer)** 

**Common Stock, par value $0.0001 per share** 

**(Title of Class of Securities)** 

**254604101** 

**(CUSIP Number)** 

**Alejandro Moreno** 

**Langhorne S. Perrow** 

**c/o Access Industries, Inc.** 

**40 West 57<sup>th</sup> Street, 28th Floor** 

**New York, New York 10019** 

**(212) 247-6400** 

*with copies to*:

**Nicholas P. Pellicani** 

**Debevoise & Plimpton LLP** 

**65 Gresham Street** 

**EC2V 7NQ** 

**London** 

**+ 44 20 7786 9000** 

**Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)** 

**December 29, 2022** 

**(Date of Event which Requires Filing of this Statement)** 

------

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

------

CUSIP No. 254604101

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON.<br>&nbsp;&nbsp;&nbsp;&nbsp;AI DMI LLC |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC USE ONLY |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;SOURCE OF FUNDS (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;SC |
| &nbsp;&nbsp;&nbsp; 5 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp; 6 | &nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>&nbsp;&nbsp;&nbsp;&nbsp;State of Delaware |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;7 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 10 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 shares |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;13 | &nbsp;&nbsp;&nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);<br>&nbsp;&nbsp;&nbsp;&nbsp;16.00%<sup>(1)</sup> |
| &nbsp;&nbsp;&nbsp;14 | &nbsp;&nbsp;&nbsp;&nbsp;TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;OO (Limited Liability Company) |

---

(1) Based on 16,923,285 shares of Common Stock outstanding, as of December 29, 2022, as reported in the
Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on December 29, 2022.

------

CUSIP No. 254604101

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON.<br>&nbsp;&nbsp;&nbsp;&nbsp;Access Industries Holdings LLC |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC USE ONLY |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;SOURCE OF FUNDS (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;SC |
| &nbsp;&nbsp;&nbsp; 5 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp; 6 | &nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>&nbsp;&nbsp;&nbsp;&nbsp;United States of America |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;7 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 10 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;13 | &nbsp;&nbsp;&nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);<br>&nbsp;&nbsp;&nbsp;&nbsp;16.00%<sup>(1)</sup> |
| &nbsp;&nbsp;&nbsp;14 | &nbsp;&nbsp;&nbsp;&nbsp;TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;OO (Limited Liability Company) |

---

(1) Based on 16,923,285 shares of Common Stock outstanding, as of December 29, 2022, as reported in the
Issuer's Current Report on Form 8-K filed with the SEC on December 29, 2022.

------

CUSIP No. 254604101

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON.<br>&nbsp;&nbsp;&nbsp;&nbsp;Access Industries Management, LLC |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC USE ONLY |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;SOURCE OF FUNDS (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;SC |
| &nbsp;&nbsp;&nbsp; 5 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp; 6 | &nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>&nbsp;&nbsp;&nbsp;&nbsp;State of Delaware |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;7 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 10 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;13 | &nbsp;&nbsp;&nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);<br>&nbsp;&nbsp;&nbsp;&nbsp;16.00%<sup>(1)</sup> |
| &nbsp;&nbsp;&nbsp; 14 | &nbsp;&nbsp;&nbsp;&nbsp;TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;OO (Limited Liability Company) |

---

(1) Based on 16,923,285 shares of Common Stock outstanding, as of December 29, 2022, as reported in the
Issuer's Current Report on Form 8-K filed with the SEC on December 29, 2022.

------

CUSIP No. 254604101

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;NAME OF REPORTING PERSON.<br>&nbsp;&nbsp;&nbsp;&nbsp;Len Blavatnik |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC USE ONLY |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;SOURCE OF FUNDS (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;SC |
| &nbsp;&nbsp;&nbsp; 5 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp; 6 | &nbsp;&nbsp;&nbsp;&nbsp;CITIZENSHIP OR PLACE OF ORGANIZATION<br>&nbsp;&nbsp;&nbsp;&nbsp;United States of America |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;7 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED VOTING POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;SOLE DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;0 shares |
| &nbsp;&nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY <br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 10 | &nbsp;&nbsp;&nbsp;&nbsp;SHARED DISPOSITIVE POWER<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>&nbsp;&nbsp;&nbsp;&nbsp;2,706,976 shares |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;13 | &nbsp;&nbsp;&nbsp;&nbsp;PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11);<br>&nbsp;&nbsp;&nbsp;&nbsp;16.00%<sup>(1)</sup> |
| &nbsp;&nbsp;&nbsp; 14 | &nbsp;&nbsp;&nbsp;&nbsp;TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)<br>&nbsp;&nbsp;&nbsp;&nbsp;IN |

---

(1) Based on 16,923,285 shares of Common Stock outstanding, as of December 29, 2022, as reported in the
Issuer's Current Report on Form 8-K filed with the SEC on December 29, 2022.

------

CONTINUATION PAGES TO SCHEDULE 13D

This Schedule 13D is being filed by AI DMI LLC ("AI DMI"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik (collectively, the "Reporting Persons", and each, a "Reporting Person"), in respect of the common stock, par value $0.0001 per share (the "Common Stock"), of Disc Medicine, Inc. (the "Issuer"). The shares of Common Stock of the Issuer are listed on the Nasdaq Global Market under the symbol "IRON."

---

| | |
|:---|:---|
| **Item 1** | **Security and Issuer**  |

---

This Schedule 13D relates to the Common Stock of the Issuer. The address of the Issuer's principal executive office is: 321 Arsenal Street, Suite 101, Watertown, MA 02472.

---

| | |
|:---|:---|
| **Item 2** | **Identity and Background**  |

---

---

| | | |
|:---|:---|:---|
| **Name** | **Principal Business/Occupation** | **Jurisdiction of**<br> **Organization/Citizenship** |
| AI DMI LLC c/o Access Industries, Inc.<br> 40 West 57<sup>th</sup> Street, 28<sup>th</sup> Fl.<br> New York, NY 10019 | Holding company for a strategic investment | Delaware |
| Access Industries Holdings LLC c/o Access Industries, Inc.<br> 40 West 57<sup>th</sup> Street, 28<sup>th</sup> Fl.<br> New York, NY 10019 | Holding strategic investments in a variety of industries worldwide | Delaware |
| Access Industries Management, LLC c/o Access Industries, Inc.<br> 40 West 57<sup>th</sup> Street, 28<sup>th</sup> Fl.<br> New York, NY 10019 | Manager of holdings of strategic investments in a variety of industries worldwide | Delaware |
| Len Blavatnik c/o Access Industries, Inc.<br> 40 West 57<sup>th</sup> Street, 28<sup>th</sup> Fl.<br> New York, NY 10019 | Chairman of Access Industries, Inc., the principal business of which is holding strategic investments in a variety of industries worldwide | United States of America |

---

The agreement among the Reporting Persons relating to the joint filing of this Schedule 13D is filed as Exhibit 99.3 hereto.

None of the Reporting Persons has, during the last five years: (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

---

| | |
|:---|:---|
| **Item 3** | **Source and Amount of Funds or Other Considerations**  |

---

On December 29, 2022, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated August 9, 2022, and entered into by and among the Issuer (formerly known as Gemini Therapeutics, Inc.), Disc Medicine Opco, Inc. (formerly known as Disc Medicine, Inc.) ("Disc") and Gemstone Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into Disc, with Disc surviving as a wholly owned subsidiary of the Issuer (the "Merger") and Gemini Therapeutics, Inc. was renamed Disc Medicine, Inc.

------

Between September 2019 and October 2020, AI DMI acquired 11,666,667 shares of Disc Series A preferred stock at a price of $1.20 per share. In September 2021, AI DMI acquired 3,071,868 shares of Disc Series B preferred stock at a price of $2.40 per share. On December 29, 2022, AI DMI acquired 9,960,159 shares of Disc common stock, par value $0.0001 ("Disc Common Stock"), at a price of $2.51 per share. AI DMI funded such purchases using capital contributed from affiliated entities, which funded that capital using cash on hand.

In connection with and immediately prior to the consummation of the Merger, on December 29, 2022, each share of Disc Series A preferred stock and Series B preferred stock converted into a share of Disc Common Stock.

On December 29, 2022, upon consummation of the Merger, all outstanding shares of Disc Common Stock were cancelled in exchange for the right to receive shares of Common Stock on approximately a 0.1096:1 basis. Accordingly, AI DMI received 2,706,976 shares of Common Stock in connection with the Merger.

The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which was filed as Exhibit 2.1 to the Issuer's Form 8-K, as filed with the SEC on August 10, 2022.

---

| | |
|:---|:---|
| **Item 4** | **Purpose of Transaction**  |

---

The information set forth in Item 6 hereof is hereby incorporated by reference into this Item 4.

On December 29, 2022, following consummation of the Merger, the Reporting Persons beneficially owned 2,706,976 shares of Common Stock, which represented approximately 16.00% of the outstanding shares of Common Stock. See "Item 5. Interests in Securities of the Issuer." In connection with the consummation of the Merger, the Issuer's board of directors elected Liam Ratcliff, head of Biotechnology at Access Industries, Inc. (an affiliate of the Reporting Persons), to serve as a director of the Issuer. In his capacity as a director of the Issuer, Mr. Ratcliff may take an active role in working with the Issuer's management on operational, financial and strategic initiatives.

The Reporting Persons who hold Common Stock directly acquired those securities as an investment in the regular course of their businesses. The Reporting Persons and their affiliated individuals may from time to time engage in discussions with management, the Issuer's board of directors, other stockholders of the Issuer and other relevant parties concerning the business, capital allocation, operations, board composition, management, strategy and future plans of the Issuer. The Reporting Persons intend to re-examine their investment from time to time and, depending on prevailing market conditions, other investment opportunities, liquidity requirements or other investment considerations the Reporting Persons deem material, the Reporting Persons may from time to time acquire additional Common Stock in the open market, block trades, negotiated transactions, or otherwise and may also dispose of all or a portion of the Issuer's securities, in open market or privately negotiated transactions, and/or enter into derivative transactions with institutional counterparties with respect to the Issuer's securities, in each case, subject to limitations under applicable law and the Registration Rights Agreement (as defined below).

The Reporting Persons have not yet determined which, if any, of the above courses of action they may ultimately take. The Reporting Persons' future actions with regard to the Issuer are dependent on their evaluation of the factors listed above, circumstances affecting the Issuer in the future, including prospects of the Issuer, general market and economic conditions and other factors deemed relevant. The Reporting Persons reserve the right to determine in the future whether to change the purpose or purposes described above or whether to adopt plans or proposals of the type specified above or otherwise.

---

| | |
|:---|:---|
| **Item 5** | **Interest in Securities of the Issuer**  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) and (b) The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Common Stock (including, but not limited to, footnotes to such information) are incorporated herein by reference.

------

The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of shares of Common Stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including, but not limited to, footnotes to such information) are incorporated herein by reference.

2,706,976 shares of Common Stock are owned directly by AI DMI and may be deemed to be beneficially owned by AIH, AIM and Mr. Blavatnik because (i) Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH, (ii) AIM controls AIH, and (iii) AIH indirectly controls all of the outstanding voting interests in AI DMI. Each of the Reporting Persons (other than AI DMI), and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The following transactions in the Issuer's securities have been effected by Reporting Persons within the 60 days prior to this filing:

The information set forth in Item 3 of this Schedule 13D is incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Not applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Not applicable.

---

| | |
|:---|:---|
| **Item 6** | **Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer**  |

---

The information set forth in Item 3 of this Schedule 13D is incorporated by reference herein.

***Registration Rights Agreement***

In connection with the Merger, Disc entered into a Registration Rights Agreement, dated December 28, 2022 (the "Registration Rights Agreement"), with certain stockholders of Disc, including AI DMI (the "Disc Investors"), pursuant to which Disc (i) agreed to register, or cause the Issuer to register, for resale shares of Common Stock issued to the Disc Investors pursuant to the Merger Agreement (the "Registrable Securities"), and (ii) granted certain other registration rights to the Disc Investors.

In particular, the Registration Rights Agreement provides for the following registration rights:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Shelf registration rights.* No later than 45 calendar days following the completion of the Merger, the
Issuer is required to file with the SEC, a shelf registration statement registering the resale of the Registrable Securities, and use its commercially reasonable efforts to have such registration statement declared effective by the SEC as promptly
as possible.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Expenses and indemnification.* The fees, costs and expenses of registrations pursuant to the registration
rights granted to the Disc Investors under the Registration Rights Agreement will be borne by the Issuer. The Registration Rights Agreement contains customary cross-indemnification provisions, under which the Issuer is obligated to indemnify holders
of Registrable Securities in the event of material misstatements or omissions in the registration statement attributable to the Issuer, and holders of Registrable Securities are obligated to indemnify the Issuer for material misstatements or
omissions attributable to them.

Securities of the Issuer shall cease to be Registrable Securities upon the earliest to occur of (i) a registration statement with respect to the sale of such Registrable Securities is declared effective by the SEC under the Securities Act of 1933, as amended and such Registrable Securities have been disposed of by the Disc Investor in accordance with such effective registration statement, (ii) such Registrable Securities have been previously sold in accordance with Rule 144, (iii) such securities become eligible for resale without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Issuer to be in compliance with the current public information requirement under Rule 144, as determined by counsel to the Issuer pursuant to a written opinion letter to such effect, addressed, delivered and acceptable to the Issuer's transfer agent and the affected Disc Investors, and (iv) five years after the date of the Registration Rights Agreement.

------

The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the Registration Rights Agreement, which is filed as Exhibit 99.1 and incorporated herein by reference.

***Lock-up Agreement***

In connection with the execution of the Merger Agreement, on August 9, 2022, AI DMI entered into a lock-up agreement with the Issuer (the "Lock-up Agreement"). Pursuant to the terms of the Lock-up Agreement, AI DMI agreed, subject to certain exceptions, that it will not, during the period ending 180 days after the closing date of the Merger, offer to sell, pledge, sell or contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise dispose of, or any securities convertible into or exercisable or exchangeable for, enter into any swap, short sale, hedge or another arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of or publicly disclose any intention to effect any transaction previously specified in respect of shares of Common Stock held by AI DMI.

The foregoing description of the Lock-up Agreement does not purpose to be complete and is qualified in its entirety by reference to the Lock-up Agreement, which is filed as Exhibit 99.2 and incorporated herein by reference.

***Joint Filing Agreement***

A Joint Filing Agreement, dated January 9, 2023, by and among the Reporting Persons has been executed by the Reporting Persons, a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 7** | **Materials to Be Filed as Exhibits**  |

---

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | Form of Registration Rights Agreement, dated as of December 28, 2022, by and between Disc Medicine Opco, Inc. and certain of its stockholders (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 29, 2022). |
| 99.2 | Form of Lock-up Agreement, dated as of August 9, 2022, by and between Disc Medicine, Inc. and AI DMI LLC (incorporated by reference to Exhibit C to Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 10, 2022). |
| 99.3 | Joint Filing Agreement, dated as of January 9, 2023. |
| 99.4 | Limited Power of Attorney. |

---

------

**SIGNATURE** 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 9, 2023

---

| | |
|:---|:---|
| AI DMI LLC | By: Access Industries Management, LLC, its Manager |
|  | /s/ Alejandro Moreno |
|  | Name: Alejandro Moreno |
|  | Title: Executive Vice President |
| ACCESS INDUSTRIES HOLDINGS LLC | By: Access Industries Management LLC, its Manager |
|  | /s/ Alejandro Moreno |
|  | Name: Alejandro Moreno |
|  | Title: Executive Vice President |
| ACCESS INDUSTRIES MANAGEMENT, LLC | /s/ Alejandro Moreno |
|  | Name: Alejandro Moreno |
|  | Title: Executive Vice President |
|  | /s/ \* |
|  | Name: Leonard Blavatnik |

---

------

\* The undersigned, by signing his name hereto, executes this Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

---

| | |
|:---|:---|
| By: | /s/ Alejandro Moreno |
|  | Name: Alejandro Moreno |
|  | Attorney-in-Fact |

---

## Exhibit 99.3

Exhibit 99.3

**Joint Filing Agreement** 

The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (and any amendments thereto) with respect to the shares of Common Stock owned by each of them, of Disc Medicine, Inc., a corporation incorporated under the laws of the State of Delaware. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D.

[*Signature Page Follows*]

------

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 9th day of January, 2023.

---

| | |
|:---|:---|
| AI DMI LLC | By: Access Industries Management, LLC, its Manager |
|  | /s/ Alejandro Moreno |
|  | Name: Alejandro Moreno |
|  | Title: Executive Vice President |
| ACCESS INDUSTRIES HOLDINGS LLC | By: Access Industries Management LLC, its Manager |
|  | /s/ Alejandro Moreno |
|  | Name: Alejandro Moreno |
|  | Title: Executive Vice President |
| ACCESS INDUSTRIES MANAGEMENT, LLC | /s/ Alejandro Moreno |
|  | Name: Alejandro Moreno |
|  | Title: Executive Vice President |
|  | /s/ \* |
|  | Name: Len Blavatnik |

---

------

\* The undersigned, by signing his name hereto, executes this Joint Filing Agreement pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

---

| | |
|:---|:---|
| By: | /s/ Alejandro Moreno |
|  | Name: Alejandro Moreno |
|  | Attorney-in-Fact |

---

## Exhibit 99.4

Exhibit 99.4

**LIMITED POWER OF ATTORNEY** 

Know all by these presents, that the undersigned hereby constitutes and appoints Lincoln Benet and Alejandro Moreno, and each of them individually, the undersigned's true and lawful attorney-in-fact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• execute for and on behalf of the undersigned, in the undersigned's capacity as a beneficial owner of Disc
Medicine, Inc. (the " <u>Company</u> "), (i) Forms 3, 4 and 5 and any other forms required to be filed in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the " <u>Exchange Act</u> ") and
the rules thereunder (a " <u>Section</u> <u>16 Form</u> "), (ii) all forms and schedules in accordance with Section 13(d) of the Exchange Act and the rules thereunder, including all amendments thereto (a
" <u>Section</u> <u>13 Schedule</u> "), (iii) a Form ID Application, Passphrase Update Application and/or request to convert from paper only to electronic filer with the U.S. Securities and Exchange Commission and to obtain
access codes to file on EDGAR and any other forms required to be filed or submitted in accordance with Regulation S-T promulgated by the U.S. Securities and Exchange Commission (or any successor provision) in
order to file a Section 13 Schedule or a Section 16 Form electronically (a " <u>Form ID</u> ", and, together with a Section 13 Schedule and Section 16 Form, the " <u>Forms and Schedules</u> ") and (iv) any
Joint Filing Agreement or similar agreement with respect to the filing of any of the Forms or Schedules in (i) through (iii) above;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to
complete and execute any such Forms and Schedules, complete and execute any amendment or amendments thereto, and timely file such Forms and Schedules with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• take any other action of any type whatsoever in connection with the foregoing which, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by each such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such terms and conditions as he may approve in
his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that each such attorney-in-fact is serving in such capacity at the request of the undersigned, and is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 or Section 16 of the Exchange Act.

The Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Forms and Schedules with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.

From and after the date hereof, any Limited Power of Attorney previously granted by the undersigned concerning the subject matter hereof is hereby revoked.

IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of January 9, 2023.

---

| |
|:---|
| LEONARD BLAVATNIK |
| /s/ Leonard Blavatnik |

---